Most Popular
-
6
[Graphic News] More Koreans say they plan long-distance trips this year
![[Graphic News] More Koreans say they plan long-distance trips this year](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/17/20240417050828_0.gif&u=)
-
7
[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
-
8
North Korea removes streetlights along cross-border roads with South
-
9
Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
-
10
Farming households dip below 1m for first time in 2023
![[Graphic News] More Koreans say they plan long-distance trips this year](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/17/20240417050828_0.gif&u=)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
[THE INVESTOR] Biotechnology firm Nature Cell announced on Aug. 30 that it has obtained the license to culture adult stem cells from Japan’s pharmaceuticals agency.
The company said that Japan’s Ministry of Health, Labor and Welfare granted the permit to manufacture products based on specific types of cells.
The company had applied for the permit on Feb. 15, and the Pharmaceuticals and Medical Devices Agency approved the company’s facilities after a two-day on-site review in June.
The permit lays the ground for the company to use its technologies including those regarding platelet rich plasma and immune cells in Japan. The company plans to use platelet rich plasma, immune and stem cells, and other technologies to develop treatments for infertility, immune system and skin related conditions.
Choi He-suk (cheesuk@heraldcorp.com)
The company said that Japan’s Ministry of Health, Labor and Welfare granted the permit to manufacture products based on specific types of cells.
The company had applied for the permit on Feb. 15, and the Pharmaceuticals and Medical Devices Agency approved the company’s facilities after a two-day on-site review in June.
The permit lays the ground for the company to use its technologies including those regarding platelet rich plasma and immune cells in Japan. The company plans to use platelet rich plasma, immune and stem cells, and other technologies to develop treatments for infertility, immune system and skin related conditions.
Choi He-suk (cheesuk@heraldcorp.com)
![[From the Scene] Monks, Buddhists hail return of remains of Buddhas](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/19/20240419050617_0.jpg&u=20240419175937)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
![[Today’s K-pop] Illit drops debut single remix](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/04/19/20240419050612_0.jpg&u=)